Premium
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa
Author(s) -
John B. Penney,
David Oakes,
Ira Shoulson,
Stanley Fahn,
Anthony E. Lang,
J. William Langston,
Peter A. LeWitt,
C. Warren Olanow,
Caroline M. Tanner,
Karl Kieburtz
Publication year - 1996
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410390107
Subject(s) - levodopa , selegiline , parkinson's disease , parkinsonism , medicine , adverse effect , disease , degenerative disease , tocopherol , vitamin e , antioxidant , chemistry , biochemistry
The Deprenyl and Tocopherol Antioxidant Therapy of Parkinsonism (DATATOP) trial was designed to test outcomes from treatment with 10 mg of deprenyl and/or 2,000 mg of tocopherollday in 800 untreated patients with Parkinson's disease. The need of subjects for symptomatic treatment with levodopa and the conversion of all subjects to open‐label deprenyl made it possible to study the long‐term effect of early deprenyl and tocopherol treatment on the later development of levodopa‐associated side effects. The rate of developing these side effects did not differ among the original treatment groups (early versus late deprenyl and tocopherol versus nontocopherol). About 50% of subjects developed “wearing off,” 30% dyskinesias, and 25% “freezing” in each group. At the end of the study, the groups were similarly disabled on the Hoehn‐Yahr, Schwab‐England, and Unified Parkinsonapos;s Disease Rating scales and took similar amounts of levodopa. Young subjects were more likely to develop wearing off, women to develop dyskinesias, and older subjects with rapidly progressive disease to develop freezing. We conclude that prior treatment with deprenyl or tocopherol did not reduce the occurrence of subsequent levodopa‐associated adverse effects in this population.